Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27313086

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2016 Aug 6
First author
Hermine O

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2016 Aug 6;388(10044):535-6. doi: 10.1016/S0140-6736(16)30451-2.
    note
    Source null
    related pmid
    27313085
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2016 Aug;13(8):464-5. doi: 10.1038/nrclinonc.2016.104.
    note
    Source null
    related pmid
    27349195
    relationship
    Comment in

Authors and identifiers

  1. name
    Hermine O
    type
    Author
  2. name
    Hoster E
    type
    Author
  3. name
    Walewski J
    type
    Author
  4. name
    Bosly A
    type
    Author
  5. name
    Stilgenbauer S
    type
    Author
  6. name
    Thieblemont C
    type
    Author
  7. name
    Szymczyk M
    type
    Author
  8. name
    Bouabdallah R
    type
    Author
  9. name
    Kneba M
    type
    Author
  10. name
    Hallek M
    type
    Author
  11. name
    Salles G
    type
    Author
  12. name
    Feugier P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Hermine O
    type
    Author
  2. name
    Hoster E
    type
    Author
  3. name
    Walewski J
    type
    Author
  4. name
    Bosly A
    type
    Author
  5. name
    Stilgenbauer S
    type
    Author
  6. name
    Thieblemont C
    type
    Author
  7. name
    Szymczyk M
    type
    Author
  8. name
    Bouabdallah R
    type
    Author
  9. name
    Kneba M
    type
    Author
  10. name
    Hallek M
    type
    Author
  11. name
    Salles G
    type
    Author
  12. name
    Feugier P
    type
    Author
bibliography ids
  1. nci-bib-8f1496d8c53db4e660c06537
book metadata
content sha256
9e1e0b7eed3847aba25398565ee9eab90e33e531ebc5965ec69d97561b8efcb4
document type
citation
dois
  1. 10.1016/S0140-6736(16)00739-X
electronic publication date
display
2016 Jun 14
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27313086
immutable id
pubmed:27313086@9e1e0b7eed3847aba25398565ee9eab90e33e531ebc5965ec69d97561b8efcb4
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10044
name
Lancet (London, England)
nlm unique id
2985213R
pages
565-75
volume
388
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2016 Aug 6;388(10044):535-6. doi: 10.1016/S0140-6736(16)30451-2.
    note
    Source null
    related pmid
    27313085
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2016 Aug;13(8):464-5. doi: 10.1038/nrclinonc.2016.104.
    note
    Source null
    related pmid
    27349195
    relationship
    Comment in
outcomes validated
false
pmid
27313086
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
86105fff0be260d1a1b1057f5daefe785ab6c0bb536ad3b22b01791753d68eed
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Aug 6
precision
day
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27313086/
title
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Preserved source evidence · Not medical advice